The Translational and Regulatory Development of an Implantable Microdevice for Multiple Drug Sensitivity Measurements in Cancer Patients - PubMed (original) (raw)
. 2022 Jan;69(1):412-421.
doi: 10.1109/TBME.2021.3096126. Epub 2021 Dec 23.
Sharath Bhagavatula, Elizabeth Stover, Kyle Deans, Cecilia Larocca, Yolanda Colson, Pierpaolo Peruzzi, Adam Kibel, Nobuhiko Hata, Lillian Tsai, Yin Hung, Robert Packard, Oliver Jonas
- PMID: 34242160
- PMCID: PMC8702455
- DOI: 10.1109/TBME.2021.3096126
The Translational and Regulatory Development of an Implantable Microdevice for Multiple Drug Sensitivity Measurements in Cancer Patients
Christine Dominas et al. IEEE Trans Biomed Eng. 2022 Jan.
Abstract
Objective: The purpose of this article is to report the translational process of an implantable microdevice platform with an emphasis on the technical and engineering adaptations for patient use, regulatory advances, and successful integration into clinical workflow.
Methods: We developed design adaptations for implantation and retrieval, established ongoing monitoring and testing, and facilitated regulatory advances that enabled the administration and examination of a large set of cancer therapies simultaneously in individual patients.
Results: Six applications for oncology studies have successfully proceeded to patient trials, with future applications in progress.
Conclusion: First-in-human translation required engineering design changes to enable implantation and retrieval that fit with existing clinical workflows, a regulatory strategy that enabled both delivery and response measurement of up to 20 agents in a single patient, and establishment of novel testing and quality control processes for a drug/device combination product without clear precedents.
Significance: This manuscript provides a real-world account and roadmap on how to advance from animal proof-of-concept into the clinic, confronting the question of how to use research to benefit patients.
Figures
Fig. 1.
The IMD. The IMD is inserted into tumors where it releases microdoses of drugs at controlled time points (a). There are 20 microreservoirs, each containing a different drug or drug combination (colorcoded in the photograph to visualize each reservoir’s pore). The IMD is attached to a guidewire and is deployed via a needle (b).
Fig. 2.
Timeline of regulatory review process. After FDA IND submission, the FDA has 30 days to review the application and provide any concerns that must be addressed. The IRB submission process is similar, but typically has a longer timeline.
Fig. 3.
IMD preparatory steps for clinical trial. Preparation of the IMD for clinical trial involves a thorough material disinfection and drug formulation process, drug loading at the pharmacy, sterilization of samples, and endotoxin and sterility testing.
Fig. 4.
The patient journey. After confirming eligibility, patients undergo either an intra-operative, image-guided, or cutaneous IMD implantation. Depending on which implantation method was used, the patient then undergoes an intra-operative or cutaneous retrieval. The tissue is then analyzed and findings are presented to the involved clinicians and the FDA.
Fig. 5.
IMD implantation and retrieval. In prostate, ovarian, and breast cancer trials, IMDs are implanted using an image-guided approach, visualized in the red circle on the prostate CT-scan (a). IMDs are retrieved during surgery 48–72 hours later, with confirmation using a specimen X-ray (d). In the glioblastoma trial, IMDs are implanted at the beginning of surgery (b) and retrieved at the end (e). In the CTCL trial, devices are implanted using a cutaneous method in an outpatient setting (c) and retrieved using a punch biopsy tool (f).
Fig. 6.
Iterative design changes to the IMD. The initial IMD prototype was a basic cylinder with reservoirs. A conical tip, widened base, and guidewire were later added. For the CTCL trial, the IMD was re-designed to include a wider and flatter base and elimination of the guidewire.
Fig. 7.
Tumor drug response readouts. Drug concentration is measured by autofluorescence or mass spectrometry (a). Drug effects are visualized by immunohistochemistry (b) and TME remodeling (c). MALDI can be used to analyze changes in the local tumor metabolism (d) and spatial transcriptomics focuses on the expression of over 1800 genes (e). Ultimately, a systems-level analysis is conducted for each drug (f).
Similar articles
- An interventional image-guided microdevice implantation and retrieval method for in-vivo drug response assessment.
Bhagavatula SK, Upadhyaya K, Miller BJ, Bursch P, Lammers A, Cima MJ, Silverman SG, Jonas O. Bhagavatula SK, et al. Med Phys. 2019 Nov;46(11):5134-5143. doi: 10.1002/mp.13803. Epub 2019 Sep 26. Med Phys. 2019. PMID: 31494942 Free PMC article. - Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P. Crider K, et al. Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article. - Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Myerson AS, Krumme M, Nasr M, Thomas H, Braatz RD. Myerson AS, et al. J Pharm Sci. 2015 Mar;104(3):832-9. doi: 10.1002/jps.24311. Epub 2014 Dec 26. J Pharm Sci. 2015. PMID: 25546650 Review. - Critical challenges to the design of drug-eluting medical devices.
Luk A, Junnarkar G. Luk A, et al. Ther Deliv. 2013 Apr;4(4):471-7. doi: 10.4155/tde.13.17. Ther Deliv. 2013. PMID: 23557288 Review. - [Development of antituberculous drugs: current status and future prospects].
Tomioka H, Namba K. Tomioka H, et al. Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
Cited by
- Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.
Peruzzi P, Dominas C, Fell G, Bernstock JD, Blitz S, Mazzetti D, Zdioruk M, Dawood HY, Triggs DV, Ahn SW, Bhagavatula SK, Davidson SM, Tatarova Z, Pannell M, Truman K, Ball A, Gold MP, Pister V, Fraenkel E, Chiocca EA, Ligon KL, Wen PY, Jonas O. Peruzzi P, et al. Sci Transl Med. 2023 Sep 6;15(712):eadi0069. doi: 10.1126/scitranslmed.adi0069. Epub 2023 Sep 6. Sci Transl Med. 2023. PMID: 37672566 Free PMC article. - Engineering the Tumor Immune Microenvironment through Minimally Invasive Interventions.
Pal K, Sheth RA. Pal K, et al. Cancers (Basel). 2022 Dec 29;15(1):196. doi: 10.3390/cancers15010196. Cancers (Basel). 2022. PMID: 36612192 Free PMC article. Review. - Bendable long graded index lens microendoscopy.
Liu G, Kang JW, Bhagavatula S, Ahn SW, So PTC, Tearney GJ, Jonas O. Liu G, et al. Opt Express. 2022 Sep 26;30(20):36651-36664. doi: 10.1364/OE.468827. Opt Express. 2022. PMID: 36258589 Free PMC article. - Strategic, feasibility, economic, and cultural aspects of phase 0 approaches: Is it time to change the drug development process in order to increase productivity?
Burt T, Roffel AF, Langer O, Anderson K, DiMasi J. Burt T, et al. Clin Transl Sci. 2022 Jun;15(6):1355-1379. doi: 10.1111/cts.13269. Epub 2022 Apr 21. Clin Transl Sci. 2022. PMID: 35278281 Free PMC article. Review.
References
- Gundle KR et al., “Multiplexed evaluation of microdosed antineoplastic agents in situ in the tumor microenvironment of patients with soft tissue sarcoma,” Clin. Cancer Res.: Official J. Amer. Assoc. Cancer Res., vol. 26, no. 15, 2020. - PubMed
- Gurman P et al., “Clinical applications of biomedical microdevices for controlled drug delivery,” Mayo Clinic Proc., vol. 90, no. 1, 2015. - PubMed
- Pammolli F, Magazzini L, and Riccaboni M, “The productivity crisis in pharmaceutical R&D,” Nat. Rev. Drug Discov, vol. 10, no. 6, 2011. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R37 CA252312/CA/NCI NIH HHS/United States
- K08 CA237871/CA/NCI NIH HHS/United States
- R01 NS116144/NS/NINDS NIH HHS/United States
- P41 EB015898/EB/NIBIB NIH HHS/United States
- R01 EB030539/EB/NIBIB NIH HHS/United States
- P41 EB028741/EB/NIBIB NIH HHS/United States
- K08 NS101091/NS/NINDS NIH HHS/United States
- R37 CA224144/CA/NCI NIH HHS/United States
- R01 CA232174/CA/NCI NIH HHS/United States
- R21 CA216796/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical